ProMIS Neurosciences Stock Forecast, Price & News

-0.01 (-4.44 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: C$0.22
50-Day Range
MA: C$0.16
52-Week Range
Now: C$0.22
Volume352,210 shs
Average Volume437,952 shs
Market CapitalizationC$65.78 million
P/E RatioN/A
Dividend YieldN/A
ProMIS Neurosciences, Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson's disease (PD). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platformÂProMIS and Collective Coordinates to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb); PMN350, a mAb targeting on toxic amyloid beta oligomers (AÃO); and PMN330, a monoclonal antibody targeting toxic prionlike forms of AÃO for AD. The company is also developing therapeutics targeting the neurotoxic form of the tau protein in AD; and superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in PD and Lewy body dementia. The company has a collaboration with BC Neuroimmunology to develop and commercialize proprietary diagnostic assays; and BC Neuroimmunology to develop and offer blood-based diagnostic tests for Alzheimer's diseases. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesC$1,787.00
Price / Sales36,809.88
Cash FlowC$0.00 per share
Book ValueC$0.00 per share



Market CapC$65.78 million
Next Earnings Date5/12/2021 (Estimated)
OptionableNot Optionable


IIROC Trading Halt - PMN
March 22, 2021 |  markets.businessinsider.com
ProMIS Neurosciences Inc
January 17, 2021 |  cnbc.com
ProMIS Neurosciences Completes Offering of Special Warrants
November 16, 2020 |  finance.yahoo.com
ProMIS Neurosciences Announces Third Quarter 2020 Results
November 11, 2020 |  finance.yahoo.com
PMN.TO: ProMIS and BCNI Team Up for AD Test
November 4, 2020 |  finance.yahoo.com
PMN.TO: Serology Testing JV in AD and COVID
August 28, 2020 |  finance.yahoo.com
See More Headlines


Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.01 (-4.44 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PMN News and Ratings via Email

Sign-up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ProMIS Neurosciences (TSE:PMN) Frequently Asked Questions

What stocks does MarketBeat like better than ProMIS Neurosciences?

Wall Street analysts have given ProMIS Neurosciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProMIS Neurosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ProMIS Neurosciences' next earnings date?

ProMIS Neurosciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 12th 2021.
View our earnings forecast for ProMIS Neurosciences

How has ProMIS Neurosciences' stock been impacted by Coronavirus?

ProMIS Neurosciences' stock was trading at C$0.18 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PMN stock has increased by 19.4% and is now trading at C$0.22.
View which stocks have been most impacted by COVID-19

Who are ProMIS Neurosciences' key executives?

ProMIS Neurosciences' management team includes the following people:
  • Mr. Eugene Williams, Exec. Chairman (Age 62, Pay $558.41k)
  • Dr. Elliot Goldstein, Pres, CEO & Director (Age 70, Pay $558.11k)
  • Dr. Neil R. Cashman, Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director
  • Mr. Daniel E. Geffken M.B.A., MBA, Chief Financial Officer (Age 64, Pay $86.07k)
  • Dr. Johanne Kaplan, Chief Devel. Officer
  • Dr. Steven S. Plotkin Ph.D., Chief Physics Officer
  • Dr. Ernest D. Bush, Head of Pharmacology/Toxicology
  • Mr. Russell Blacher, Head of Manufacturing

Who are some of ProMIS Neurosciences' key competitors?

What other stocks do shareholders of ProMIS Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProMIS Neurosciences investors own include CRISPR Therapeutics (CRSP), Aurora Cannabis (ACB), (KDP), Biocept (BIOC), Spectra7 Microsystems (SEV), Flexion Therapeutics (FLXN), Onconova Therapeutics (ONTX), TherapeuticsMD (TXMD), Bonavista Energy Co. (BNP.TO) (BNP) and QEP Resources (QEP).

What is ProMIS Neurosciences' stock symbol?

ProMIS Neurosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "PMN."

How do I buy shares of ProMIS Neurosciences?

Shares of PMN and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is ProMIS Neurosciences' stock price today?

One share of PMN stock can currently be purchased for approximately C$0.22.

How much money does ProMIS Neurosciences make?

ProMIS Neurosciences has a market capitalization of C$65.78 million and generates C$1,787.00 in revenue each year.

What is ProMIS Neurosciences' official website?

The official website for ProMIS Neurosciences is www.amorfix.com.

Where are ProMIS Neurosciences' headquarters?

ProMIS Neurosciences is headquartered at 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada.

How can I contact ProMIS Neurosciences?

ProMIS Neurosciences' mailing address is 1920 Yonge St Suite 200, TORONTO, ON M4S 3E2, Canada. The company can be reached via phone at +1-416-8476898.

This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.